NCT06098079: An ongoing trial by Currax Pharmaceuticals
This trial is ongoing. It must report results 4 years, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06098079 |
|---|---|
| Title | A Phase IV Study to Assess the Effect of Naltrexone Hydrochloride Extended Release (ER) and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on the Occurrence of Major Adverse Cardiovascular Events |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 3, 2024 |
| Completion date | Jan. 31, 2029 |
| Required reporting date | Jan. 31, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |